



Express Mail No.: EV 335 859 742 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Chen et al.	Confirmation No.:	7224
Serial No.:	09/735,296	Art Unit:	1632
Filed:	January 14, 2000	Examiner:	Li, Qian Janice
For:	COMBINATION THERAPY OF CANCER BY THE ACTIVATION OF CO- STIMULATORY MOLECULES EXPRESSED BY IMMUNE CELLS AND CYTOKINES	Attorney Docket No:	6923-084

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97 & §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references C01-C03 listed on the attached revised PTO-1449 Form. Copies of references C01-C03 are enclosed.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of an "Information Disclosure Citation in an Application".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a request for continued

examination under § 1.114, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.


Date: May 7, 2004

Respectfully submitted,

*Laura A. Coruzzi* 30,742  
\_\_\_\_\_  
Laura A. Coruzzi (Reg. No.)  
**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Enclosures

*By - Doug P. Wm*  
*Reg. No: 44,412*



Express Mail No.: EV 335 859 742 US

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

6923-084-999

APPLICATION NO

09/735,296

APPLICANT

Chen et al.

FILING DATE

January 14, 2000

GROUP

1632

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01						
	A02						
	A03						
	A04						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Hirschowitz and Crystal, 1999, Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases. Am J Respir Cell Mol Biol. 20(5):935-941
	C02	Siders et al., 1998, T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J Immunol. 160(11):5465-5474
	C03	Worth et al., 2000, Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 6(9):3713-3718
	C04	
	C05	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.